EV/EBITDA - Protagonist Therapeutics Inc (NASDAQ:PTGX) - Alpha Spread

Protagonist Therapeutics Inc
NASDAQ:PTGX

Watchlist Manager
Protagonist Therapeutics Inc Logo
Protagonist Therapeutics Inc
NASDAQ:PTGX
Watchlist
Price: 45.92 USD 2.57% Market Closed
Market Cap: 2.7B USD
Have any thoughts about
Protagonist Therapeutics Inc?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

13.9
Current
-4.2
Median
5.1
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
13.9
=
Enterprise Value
2.1B USD
/
EBITDA
153.2m USD
All Countries
Close

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
11.3
2-Years Forward
EV/EBITDA
-13.2
3-Years Forward
EV/EBITDA
-26.5

See Also

Discover More